Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Non-Current Deffered Revenue (2024 - 2025)

Valion Bio has reported Non-Current Deffered Revenue over the past 2 years, most recently at $301000.0 for Q2 2025.

  • For Q2 2025, Non-Current Deffered Revenue changed N/A year-over-year to $301000.0; the TTM value through Jun 2025 reached $301000.0, changed N/A, while the annual FY2024 figure was $49000.0, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q2 2025 was $301000.0 at Valion Bio, up from $170000.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $301000.0 in Q2 2025 and troughed at $49000.0 in Q4 2024.